Thomas Davis, MD
Family Medicine · Oakdale, LANPI 1548320161
Payments from drug & device makers
Across 127 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$367
- Novartis$199
- Sunovion Pharmaceuticals Inc.$176
- Lilly USA, LLC$175
- AbbVie$167
- AstraZeneca$106
- plus $570 from 14 others
What the payments were for
- Food & beverage$1,74999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $367 |
| Novartis | 12 | $199 |
| Sunovion Pharmaceuticals Inc. | 24 | $176 |
| Lilly USA, LLC | 12 | $175 |
| AbbVie(2 entities) | 10 | $167 |
| AstraZeneca | 7 | $106 |
| Mylan Specialty L.p. | 6 | $89 |
| Amgen | 4 | $67 |
| GSK | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Pfizer | 3 | $45 |
| Abbott | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Collaborative Care Diagnostics, LLC | 1 | $24 |
| Exact Sciences | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,760 in reported general payments places this provider in the 65th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $177,549 |
| JardianceEmpagliflozin | 209 | $118,818 |
| EliquisApixaban | 213 | $112,160 |
| TrulicityDulaglutide | 70 | $98,911 |
| IngrezzaValbenazine Tosylate | 24 | $93,548 |
| MounjaroTirzepatide | 60 | $74,165 |
| RybelsusSemaglutide | 50 | $60,107 |
| LinzessLinaclotide | 95 | $56,758 |
| FarxigaDapagliflozin Propanediol | 80 | $49,464 |
| EntrestoSacubitril/Valsartan | 49 | $42,491 |
| NuplazidPimavanserin Tartrate | 16 | $39,769 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $39,436 |
| XareltoRivaroxaban | 61 | $34,969 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $30,123 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $24,175 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $367 | $237,656226 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $175 | $173,076130 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $34 | $129,969223 claims |
| PfizerEliquis, Premarin | $45 | $119,358233 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $59 | $69,55986 claims |
| AbbVieLinzess, Vraylar | $167 | $67,369110 claims |
| AstraZenecaFarxiga, Brilinta | $106 | $58,562106 claims |
| NovartisEntresto | $199 | $42,49149 claims |
| Sanofi-aventis U.S. LLCMultaq | $54 | $14,33926 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $56 | $6,50611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Oakdale
- David GuillotOakdale$15K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.